GT Biopharma shareholders approve all proposals including authorized share reduction and 2022 Omnibus Incentive Plan

GT Biopharma, Inc.

Elected directors Breen, Shrotriya, and Wendel with majority support (for votes 58-61% of shares present).
Ratified Weinberg & Company as independent auditor for FY2022 (19.7M for, 0.2M against).
Approved 2022 Omnibus Incentive Plan authorizing up to 5M shares of common stock.
Approved amendment to reduce authorized common stock from 750M to 250M shares (19.6M for).
Advisory say-on-pay passed (63.7% of votes cast) and frequency set at 1 year (11.9M for).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.